Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
A Phase 1 Trial of 225Actinium-DOTA-Daratumumab in Patients with Daratumumab-refractory Multiple Myeloma: Results from First Cohorts
Flavia Pichiorri, PhD (she/her/hers)
Professor
City of Hope
La Canada , California, United States